Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
$238.03M
Dr. Thomas J. Schuetz M.D., Ph.D.
24.00
Boston, MA
Aug 13, 2021
-4.94
$-0.35
6.08
40.74
-1,597.89%
-5.20
0.12
1.50
83.70
40.74
-28.20%
-28.67%
Similar stocks (17)
IDEAYA Biosciences, Inc.
IDYA
Keros Therapeutics, Inc.
KROS
Structure Therapeutics Inc.
GPCR
Tyra Biosciences, Inc.
TYRA
AnaptysBio, Inc.
ANAB
Cullinan Oncology, Inc.
CGEM
Replimune Group, Inc.
REPL
PureTech Health plc
PRTC
Monte Rosa Therapeutics, Inc.
GLUE
MeiraGTx Holdings plc
MGTX
PepGen Inc.
PEPG
Gossamer Bio, Inc.
GOSS
Vigil Neuroscience, Inc.
VIGL
Nuvectis Pharma, Inc.
NVCT
Aerovate Therapeutics, Inc.
AVTE
Kronos Bio, Inc.
KRON
Lyra Therapeutics, Inc.
LYRA
ETF Exposure (20)
iShares Micro-Cap ETF
IWC
0.04108%
iShares Russell 2000 Value ETF
IWN
0.01149%
Vanguard Russell 2000 Value Index Fund
VTWV
0.01%
iShares Russell 2000 ETF
IWM
0.00569%
ProShares Ultra Russell2000
UWM
0.002250694285262741%
ProShares UltraPro Russell2000
URTY
0.0011097878908537277%
ProShares Hedge Replication ETF
HDG
9.415254665692398e-4%
iShares Russell 3000 ETF
IWV
3.5e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (17)
IDEAYA Biosciences, Inc.
IDYA
Keros Therapeutics, Inc.
KROS
Structure Therapeutics Inc.
GPCR
Tyra Biosciences, Inc.
TYRA
AnaptysBio, Inc.
ANAB
Cullinan Oncology, Inc.
CGEM
Replimune Group, Inc.
REPL
PureTech Health plc
PRTC
Monte Rosa Therapeutics, Inc.
GLUE
MeiraGTx Holdings plc
MGTX
PepGen Inc.
PEPG
Gossamer Bio, Inc.
GOSS
Vigil Neuroscience, Inc.
VIGL
Nuvectis Pharma, Inc.
NVCT
Aerovate Therapeutics, Inc.
AVTE
Kronos Bio, Inc.
KRON
Lyra Therapeutics, Inc.
LYRA
ETF Exposure (20)
iShares Micro-Cap ETF
IWC
0.04108%
iShares Russell 2000 Value ETF
IWN
0.01149%
Vanguard Russell 2000 Value Index Fund
VTWV
0.01%
iShares Russell 2000 ETF
IWM
0.00569%
ProShares Ultra Russell2000
UWM
0.002250694285262741%
ProShares UltraPro Russell2000
URTY
0.0011097878908537277%
ProShares Hedge Replication ETF
HDG
9.415254665692398e-4%
iShares Russell 3000 ETF
IWV
3.5e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Extended Market Index Fund
VXF
0%